<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="6626">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03020667</url>
  </required_header>
  <id_info>
    <org_study_id>P1-PMC-01-JP</org_study_id>
    <nct_id>NCT03020667</nct_id>
  </id_info>
  <brief_title>Japanese Post-Market Cohort Study</brief_title>
  <official_title>An Observational Cohort Study in Japan to Assess the Patterns of Product Use and Changes in Health Status Associated With the Use of HeatSticks With the THS 2.2 Tobacco Heating System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Tobacco Heating System (THS 2.2) which is commercialized under the iQOS brand name (as
      described in the study protocol) in Japan is subject to an assessment program which includes
      post-market studies such as the Japanese Post-Market Cohort Study.

      The objectives and endpoints of this Post-Market Cohort Study will be analyzed in the study
      population of adult tobacco users and never smokers in Japan. This includes:

        -  Provide a perspective of tobacco product use in a &quot;real world setting&quot;, where
           simultaneous use of tobacco and nicotine containing products may occur,

        -  Describe population-level changes in biomarkers of exposure (BoExp) following long
           duration of CC and THS 2.2 use,

        -  Evaluate whether there is a difference in the levels of selected clinical risk
           endpoints (CREs) between CC smokers and THS 2.2 users.

      This study is divided in 2:

        -  Main Study: the Main Study will describe the patterns of use of tobacco and nicotine
           containing products and self-reported health outcomes and health related events in CC
           smokers and THS 2.2 users. THS 2.2 users and CC smokers will be identified and invited
           for participation in the study until each annual wave of 500 participants for each
           product is filled.

        -  Clinical Sub-Study: the Clinical Sub-Study will further assess the population level
           differences in BoExp to harmful and potentially harmful constituents (HPHCs), CREs, and
           self-reported symptoms and health outcomes between CC smokers, THS 2.2 users and
           never-smokers, the latter group only included in the Clinical Sub-Study. THS 2.2 users
           enrolled in the Main Study will be invited to enroll in the Clinical Sub-Study where
           clinical assessments will be performed and biological samples (blood, serum, plasma,
           and urine) will be collected. There will be two clinical study visits, which will take
           place at Month 12 (Visit 1) and Month 36 post product initiation (Visit 2).

      Participants will be recruited into the cohort in annual waves over a period of 4 years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For THS 2.2 users, the date of initiation of THS 2.2 use is the trigger for all study
      assessments in both the Main Study and the Clinical Sub-Study.

      THS 2.2 users will be enrolled into the study at least 2 months after initiating use of THS
      2.2 (to ensure adoption of THS 2.2 after switching from CC), but less than 12 months after
      initiating use of THS 2.2 (to ensure that each annual wave targets new users), the study
      assessments will start at the next appropriate study time point after enrollment.

      The process will be different for CC smokers in the Main Study as well as CC smokers and
      never-smokers in the Clinical Sub-Study. In the Main Study, the CC smoker's assessment
      timing will be based on the date of enrollment.

      This study is an open cohort which will have a follow-up duration of up to 5 years. With a
      minimum follow-up per participant of 1 year.

      The cohort will remain open for enrollment for the first 4 years, with annual waves of 500
      THS 2.2 users and 500 CC smokers for the Main Study. 190 THS 2.2 users, 190 CC smokers and
      190 never-smokers will be enrolled annually in the Clinical Sub-Study. The aim of these
      waves is to sample from a changing pool of THS 2.2 users in order to have a population
      representative sample of those who use THS 2.2.

      As this study is observational by design and is conducted in a post-market setting, adverse
      event (AE) reporting will follow the Sponsor's established post-market Safety Surveillance
      Procedures for spontaneously reported events.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Product consumption</measure>
    <time_frame>Year 1</time_frame>
    <description>Product consumption (product use per day) is a composite outcome measure and will be calculated with the following parameters:
number of products used
mean consumption of cigarettes,
mean consumption of iQOS HeatSticks,
mean consumption of e-cigarettes
Its result will be reported as a single value for each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Product consumption</measure>
    <time_frame>Year 2</time_frame>
    <description>Product consumption (product use per day) is a composite outcome measure and will be calculated with the following parameters:
number of products used
mean consumption of cigarettes,
mean consumption of iQOS HeatSticks,
mean consumption of e-cigarettes
Its result will be reported as a single value for each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Product consumption</measure>
    <time_frame>Year 3</time_frame>
    <description>Product consumption (product use per day) is a composite outcome measure and will be calculated with the following parameters:
number of products used
mean consumption of cigarettes,
mean consumption of iQOS HeatSticks,
mean consumption of e-cigarettes
Its result will be reported as a single value for each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Product consumption</measure>
    <time_frame>Year 4</time_frame>
    <description>Product consumption (product use per day) is a composite outcome measure and will be calculated with the following parameters:
number of products used
mean consumption of cigarettes,
mean consumption of iQOS HeatSticks,
mean consumption of e-cigarettes
Its result will be reported as a single value for each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Product consumption</measure>
    <time_frame>Year 5</time_frame>
    <description>Product consumption (product use per day) is a composite outcome measure and will be calculated with the following parameters:
number of products used
mean consumption of cigarettes,
mean consumption of iQOS HeatSticks,
mean consumption of e-cigarettes
Its result will be reported as a single value for each group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-individual product use trajectories over time: Rate of tobacco and nicotine product use transitions</measure>
    <time_frame>Year 1</time_frame>
    <description>Percentage of participants that switched between products.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-individual product use trajectories over time: Rate of tobacco and nicotine product use transitions</measure>
    <time_frame>Year 2</time_frame>
    <description>Percentage of participants that switched between products.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-individual product use trajectories over time: Rate of tobacco and nicotine product use transitions</measure>
    <time_frame>Year 3</time_frame>
    <description>Percentage of participants that switched between products.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-individual product use trajectories over time: Rate of tobacco and nicotine product use transitions</measure>
    <time_frame>Year 4</time_frame>
    <description>Percentage of participants that switched between products.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intra-individual product use trajectories over time: Rate of tobacco and nicotine product use transitions</measure>
    <time_frame>Year 5</time_frame>
    <description>Percentage of participants that switched between products.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical risk endpoints associated with cardiovascular disease: high density lipoprotein cholesterol (HDL-C)</measure>
    <time_frame>Year 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical risk endpoints associated with cardiovascular disease: white blood cell count (WBC)</measure>
    <time_frame>Year 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical risk endpoints associated with cardiovascular disease: soluble intracellular adhesion molecule 1 (sICAM-1)</measure>
    <time_frame>Year 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical risk endpoints associated with cardiovascular disease: 11-dehydrothromboxane B2 (11-DTX-B2)</measure>
    <time_frame>Year 1</time_frame>
    <description>Expressed as concentration adjusted for creatinine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical risk endpoints associated with cardiovascular disease: 8-epi-prostaglandin-alpha (8-epi-PGF2Î±)</measure>
    <time_frame>Year 1</time_frame>
    <description>Expressed as concentration adjusted for creatinine</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical risk endpoints associated with cardiovascular disease: carboxyhemoglobin (COHb)</measure>
    <time_frame>Year 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical risk endpoints associated with cardiovascular disease: metabolic syndrome</measure>
    <time_frame>Year 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical risk endpoints associated with cardiovascular disease: high sensitivity C-reactive protein (hs-CRP)</measure>
    <time_frame>Year 3</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical risk endpoints associated with respiratory disease: percent predicted forced expiratory volume in 1 second (FEV1 %pred)</measure>
    <time_frame>Year 1</time_frame>
    <description>Without bronchodilator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical risk endpoints associated with respiratory disease: percent predicted forced expiratory volume in 1 second (FEV1 %pred)</measure>
    <time_frame>Year 3</time_frame>
    <description>Without bronchodilator</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL)</measure>
    <time_frame>Year 1</time_frame>
    <description>Expressed as concentration adjusted for creatinine</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">4760</enrollment>
  <condition>Smoking</condition>
  <condition>Tobacco Product</condition>
  <arm_group>
    <arm_group_label>THS 2.2 Users</arm_group_label>
    <description>The criteria defining a &quot;THS 2.2 user&quot; are listed in the section &quot;Eligibility&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC Smokers</arm_group_label>
    <description>The criteria defining a &quot;CC smoker&quot; are listed in the section &quot;Eligibility&quot;.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Never-Smokers</arm_group_label>
    <description>The criteria defining a &quot;never-smoker&quot; user are listed in the section &quot;Eligibility&quot;.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood: long-term storage of bio-banking samples for further analysis of gene expression
      (only if additional consent is given).
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        In total, a minimum of 4760 adults (female or male) will be enrolled into this study,
        additional participants may be required to meet the matching requirements for the
        Sub-Study.

        4000 participants will be enrolled in the Main Study, including 2000 THS 2.2 users and
        2000 CC smokers.

        The Sub-Study will include a minimum of 760 THS 2.2 users, 760 CC smokers and 760
        never-smokers for a total of 2280 participants. Depending on the loss of participants
        between the 1st and 2nd Clinical Sub-Study visit additional participants may be recruited
        to the Clinical Sub-Study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult tobacco users in Japan (20 years of age)

          -  The participant is Japanese

          -  Participant is able to understand the information provided in the subject information
             sheet (SIS) and informed consent form (ICF)

          -  Signed ICF

          -  Willing to participate in the study and has access to the internet

          -  For THS 2.2 users:

               -  Is currently using THS 2.2 HeatSticks

               -  Has used at least 100 THS 2.2 HeatSticks in their lifetime, and

               -  Has used THS 2.2 HeatSticks for 2 months or more

          -  For CC smokers:

               -  Is currently using CC

               -  Is not currently using THS 2.2 HeatSticks, and

               -  Has used at least 100 CC in their lifetime

          -  For never-smokers:

               -  Is not currently using CC

               -  Is not currently using THS 2.2 HeatSticks, and

               -  Has not used at least 100 CC and/or THS 2.2 HeatSticks in their lifetime

        Exclusion Criteria:

          -  Tobacco industry employees

          -  Employed by the Sponsor, CRO or Clinical Site

          -  For THS 2.2 users:

               -  More than 12 months of THS 2.2 use

          -  For the Clinical Sub-Study:

               -  For THS 2.2 users: not enrolled in the Main Study

               -  Diagnosis of cancer within the past 5 years or has active cancer

               -  Occurrence of a major cardiovascular diagnosis or event (i.e., myocardial
                  infarction, congestive heart failure, stroke) within the past year

               -  Does not have access to a telephone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kunihiko Uwatoko, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uwatoko Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gizelle Baker, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gizelle Baker, PhD</last_name>
    <phone>+41 (58) 242 2249</phone>
    <email>Gizelle.Baker@pmi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Uwatoko Clinic</name>
      <address>
        <city>Nagoya</city>
        <zip>462-0825</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kunihiko Uwatoko, PhD</last_name>
      <phone>+81-52-991-4602</phone>
      <email>uwatoko.clinic@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Kunihiko Uwatoko, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 11, 2017</lastchanged_date>
  <firstreceived_date>November 17, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Conventional cigarette</keyword>
  <keyword>iQOS</keyword>
  <keyword>Never smoker</keyword>
  <keyword>THS</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
